These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37802148)

  • 21. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2.
    Yu F; Liu X; Ou H; Li X; Liu R; Lv X; Xiao S; Hu M; Liang T; Chen T; Wei X; Zhang Z; Liu S; Liu H; Zhu Y; Liu G; Tu T; Li P; Zhang H; Pan T; Ma X
    mBio; 2024 Aug; 15(8):e0108824. PubMed ID: 38953634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
    Karthika T; Joseph J; Das VRA; Nair N; Charulekha P; Roji MD; Raj VS
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.
    Du Y; Shi R; Zhang Y; Duan X; Li L; Zhang J; Wang F; Zhang R; Shen H; Wang Y; Wu Z; Peng Q; Pan T; Sun W; Huang W; Feng Y; Feng H; Xiao J; Tan W; Wang Y; Wang C; Yan J
    Nat Commun; 2021 Aug; 12(1):5000. PubMed ID: 34404805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    Muralidar S; Gopal G; Visaga Ambi S
    J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
    Chen F; Shi Q; Pei F; Vogt A; Porritt RA; Garcia G; Gomez AC; Cheng MH; Schurdak ME; Liu B; Chan SY; Arumugaswami V; Stern AM; Taylor DL; Arditi M; Bahar I
    Mol Syst Biol; 2021 Aug; 17(8):e10239. PubMed ID: 34339582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues.
    Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Li N; Tian M; Jin N; Li X
    J Virol; 2021 Nov; 95(24):e0153721. PubMed ID: 34550769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dual inhibitor of PIP5K1C and PIKfyve prevents SARS-CoV-2 entry into cells.
    Seo Y; Jang Y; Lee SG; Rhlee JH; Kong S; Vo TTH; Kim MH; Lee MK; Kim B; Hong SY; Kim M; Lee JY; Myung K
    Exp Mol Med; 2024 Aug; 56(8):1736-1749. PubMed ID: 39085352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
    Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
    PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
    Xu G; Li Y; Zhang S; Peng H; Wang Y; Li D; Jin T; He Z; Tong Y; Qi C; Wu G; Dong K; Gou J; Liu Y; Xiao T; Qu J; Li L; Liu L; Zhao P; Zhang Z; Yuan J
    Cell Res; 2021 Dec; 31(12):1230-1243. PubMed ID: 34663909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.
    Prabhakara C; Godbole R; Sil P; Jahnavi S; Gulzar SE; van Zanten TS; Sheth D; Subhash N; Chandra A; Shivaraj A; Panikulam P; U I; Nuthakki VK; Puthiyapurayil TP; Ahmed R; Najar AH; Lingamallu SM; Das S; Mahajan B; Vemula P; Bharate SB; Singh PP; Vishwakarma R; Guha A; Sundaramurthy V; Mayor S
    PLoS Pathog; 2021 Jul; 17(7):e1009706. PubMed ID: 34252168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions between ACE2 and SARS-CoV-2 S Protein: Peptide Inhibitors for Potential Drug Developments Against COVID-19.
    Dërmaku-Sopjani M; Sopjani M
    Curr Protein Pept Sci; 2021; 22(10):729-744. PubMed ID: 34530706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.
    Ao Z; Chan M; Ouyang MJ; Olukitibi TA; Mahmoudi M; Kobasa D; Yao X
    PLoS One; 2021; 16(6):e0251649. PubMed ID: 34106944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung.
    Wang X; Luo J; Wen Z; Shuai L; Wang C; Zhong G; He X; Cao H; Liu R; Ge J; Hua R; Sun Z; Wang X; Wang J; Bu Z
    PLoS Pathog; 2022 Feb; 18(2):e1010343. PubMed ID: 35176124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.